Compare MATW & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | ANNX |
|---|---|---|
| Founded | 1850 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.2M | 726.1M |
| IPO Year | 1995 | 2020 |
| Metric | MATW | ANNX |
|---|---|---|
| Price | $19.29 | $4.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $31.33 | $17.00 |
| AVG Volume (30 Days) | 670.0K | ★ 3.5M |
| Earning Date | 11-19-2026 | 11-13-2026 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | ★ 59.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,795,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.42 | $2.54 |
| 52 Week High | $30.93 | $7.18 |
| Indicator | MATW | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 52.31 |
| Support Level | $18.58 | $3.71 |
| Resistance Level | $19.72 | $4.07 |
| Average True Range (ATR) | 0.45 | 0.26 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 73.90 | 82.26 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.